Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using a micro-organism to make a protein or polypeptide
Reexamination Certificate
2006-09-06
2011-10-25
Shafer, Shulamith H (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using a micro-organism to make a protein or polypeptide
C435S069100, C435S440000, C530S399000, C530S350000, C530S412000
Reexamination Certificate
active
08043833
ABSTRACT:
The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.
REFERENCES:
patent: 4965199 (1990-10-01), Capon et al.
patent: 6027888 (2000-02-01), Georgiou et al.
patent: 6753165 (2004-06-01), Cox et al.
patent: 6872563 (2005-03-01), Beckwith et al.
patent: 6903077 (2005-06-01), Heintz
patent: 2003/0099618 (2003-05-01), Couto et al.
patent: 2003/0104628 (2003-06-01), Hua et al.
patent: 2005/0186666 (2005-08-01), Schneider et al.
patent: WO99/15636 (1999-04-01), None
patent: WO2004/103275 (2004-12-01), None
patent: WO2005/055946 (2005-06-01), None
patent: WO2005/070138 (2005-08-01), None
patent: WO2006/050247 (2006-05-01), None
patent: W02006/103298 (2006-10-01), None
Hanning et al. 1998. Trends in Biotech. 16:54-60.
Wang et al. 2010. BMC Biotechnology 10:14.
Takeshima K. et al., The preparation and phospholipid binding property of the C2 domain of human factor VIII., Thromb. Hemost. 2003, 89:788-94.
Suh J-K. et al., Yeast flavin-containing monooxygenase generates oxidizing equivalents that control protein folding in the endoplasmic reticulum., Proc. Natl. Acad. Sci. USA, vol. 96, pp. 2687-2691, Mar. 1999.
Sahdev S. et al., Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies., Mol. Cell. Biochem., 2008, 307:249-264.
Toole J. S. et al., Molecular cloning of a cDNA encoding human antihaemophilic factor., Nature , Nov. 22, 1984, 312: 342-347.
Bessette, et al. “Efficient folding of proteins with multiple disulfide bonds in theEscherichia colicytoplasm,”PNAS96:13703-13708 (1999).
Choy and Davidson, “Gaucher's disease II. Studies on the kinetics of β-glucosidase and the effects of sodium taurocholate in normal and Gaucher tissues,”Pediat. Res.14:54-59 (1980).
Choy, “Gaucher disease: the effects of phosphatidylserine on glucocerebrosidase from normal and Gaucher fibroblasts,”Hum. Genet.67:432-436 (1984).
Ferrer et al., “Chaperonins govern growth ofEscherichia coliat low temperatures,”Nat. Biotechnol.21:1266-1267 (2003).
Frand et al., “Pathways for protein disulphide bond formation,”Trends in Cell Biol.10:203-210 (2000).
Hwang et al., “Oxidized redox state of glutathione in the endoplasmic reticulum,”Science257:1496-1502 (1992).
Jurado et al., “Production of functional single-chain Fv antibodies in the cytoplasm ofEscherichia coli,”J. Mol. Biol.320:1-10 (2002).
Kharitonenkov, A. et al., “FGF-21 as a novel metabolic regulator,”J. Clin. Invest.115:1627-1635 (2005).
Levy et al., “Production of Correctly Folded Fab Antibody Fragment in the Cytoplasm ofEscherichia colitrxB gor Mutants via the Coexpression of Molecular Chaperones,”Protein Expression and Purification23:338-347 (2001).
Ostergaard, et al., “Monitoring disulfide bond formation in the eukaryotic cytosol,”J. Cell Biol.166:337-345 (2004).
Patra, et al., “Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone fromEscherichia coli,” Protein Expr. Purif.18:182-192 (2000).
Prinz et al., “The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in theEscherichia colicytoplasm,”J. Biol Chem.272:15661-15667 (1997).
Sorensen and Mortensen, “Microbial cell factories: Soluble expression of recombinant proteins in the cytoplasm ofEscherichia coli,” BioMed Central4:1-8 (2005).
Tuggle and Fuchs, “Glutathione reductase is not required for maintenance of reduced glutathione inEscherichia coliK-12,”J. Bacteriol162:448-450 (1985).
“Novagen pET System Manual”; 10th Edition Rev. B 0403, 68 pages (2003).
“Novagen: 71352: Rosetta-gami™ 2(DE3)pLysS Competent Cells”; http://www.emdbiosciences.com/product/print/71352, 2 pages (2005).
“Novagen: 71431: Origami™ 2 Competent Cell Set”; http://www.emdbiosciences.com/product/71431, 2 pages (2005).
DeFrees Shawn A.
Johnson Karl F.
Mobasseri Aliakbar
Schwartz Marc F.
Soliman Tarik
Leydig , Voit & Mayer, Ltd.
Novo Nordisk A S
Shafer Shulamith H
LandOfFree
Expression of soluble therapeutic proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression of soluble therapeutic proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression of soluble therapeutic proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299528